Slides
Page 1
Sign inces Sight Investor Presentation August 2026
Page 2
Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements are subject to considerable risks and uncertainties. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact, including statements regarding our future results of operations, product development, market opportunity, clinical trial results and timeline, and business strategy and plans. The forward-looking statements in this presentation include, but are not limited to, statements concerning the following: the Company's projected financial results, including revenue guidance, adjusted operating expense guidance, and expectations for gross margins; estimates of the Company's addressable markets for its products, including market size, patient population estimates, and market opportunity for standalone and combination minimally invasive glaucoma surgery (MIGS) procedures; the Company's ability to successfully develop and commercialize its product pipeline, including the anticipated timing and commercial impact of the launch of the OMNI® Ultra Surgical System; the expected scope and impact of third-party payer coverage decisions, including Aetna's coverage of the Company's interventional glaucoma technologies, and estimated patient access and reimbursement trends; the Company's ability to obtain and maintain sufficient reimbursement for its products; the Company's plans to scale its commercial resources and pursue expanded market access for its interventional dry eye and interventional glaucoma technologies, including physician targeting and cross-activation of its installed customer base; the Company's strategic initiatives and objectives, including its mission to advance interventional approaches in eye care; the Company's plans to invest in commercial infrastructure; the Company's expectations with respect to tariffs and other economic matters; and regulatory requirements applicable to the Company and its products. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. Management bases these forward-looking statements on its current expectations, plans and assumptions affecting the Company’s business and industry, and such statements are based on information available to it as of the time such statements are made. Although management believes these forward-looking statements are based upon reasonable assumptions, it cannot guarantee their accuracy or completeness. Forward-looking statements are subject to and involve risks, uncertainties and assumptions that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance, or achievements predicted, assumed or implied by such forward-looking statements. Some of the risks and uncertainties that may cause actual results to materially differ from those expressed or implied by these forward-looking statements are discussed under the caption “Risk Factors” in the Company’s annual and quarterly reports with the U.S. Securities and Exchange Commission, as such may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this presentation. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own estimates and research are reliable, such estimates and research have not been verified by any independent source. The Company has proprietary rights to trademarks, trade names and service marks appearing in this presentation that are important to its business. Solely for convenience, the trademarks, trade names and service marks may appear in this presentation without the ® and ™ symbols, but any such references are not intended to indicate that the Company forgoes or will not assert, to the fullest extent under applicable law, its rights or the rights of the applicable licensors to these trademarks, trade names and service marks. All trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. The Company does not intend its use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of the Company by, these other parties. Without limitation, SIGHT SCIENCES™, SIGHT SCIENCES (with design)®, OMNI®, SION®, TEARCARE®, SMARTLIDS® and TruSync™ are trademarks of Sight Sciences, Inc. in the United States and other countries. RESTASIS® is a registered trademark of Allergan, Inc., and IRIS® is a registered trademark of the American Academy of Ophthalmology. Certain financial measures, including adjusted operating expenses (“non-GAAP financial measures”), were not prepared in accordance with generally accepted accounting principles in the United States (“GAAP") and are presented in this presentation to provide information that may assist investors in understanding the Company's financial and operating results. The Company believes these non-GAAP financial measures are important performance indicators because they exclude items that are unrelated to, and may not be indicative of, the Company's core financial and operating results. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial measures are not intended to represent, and should not be considered more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. To the extent the Company utilizes such non-GAAP financial measures in the future, it expects to calculate them using a consistent method from period to period. Consistent with Securities and Exchange Commission regulations, the Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that may be made to the Company’s GAAP financial measures in calculating the non-GAAP financial measures. For a reconciliation of non-GAAP financial measures referenced in this presentation to the most directly comparable GAAP measures, please refer to the Company's earnings release issued on August 5, 2026. | 2
Page 3
[[ Our Mission Develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing. | 3
Page 4
4 A Glimpse Ahead Innovation leader in two large, growing, underserved markets; Glaucoma and Dry Eye 1 TearCare market access has started with first two MACs establishing fee schedules 2 Strong balance sheet in place to drive commercial growth and long-term investments 3 Strong gross margins and disciplined operating expense spend 4 Return to double digit revenue growth in 2026 5 | 4 The intersection of Interventional Glaucoma and Interventional Dry Eye is underway 6
Page 5
| 5 INTERVENTIONAL GLAUCOMA (IG) INTERVENTIONAL DRY EYE (IDE) The Intersection of Intervention
Page 6
6 IG + IDE and The Intersection of Intervention Shared customer base — the same providers can treat both glaucoma and dry eye patients 1 Commercial synergies across IG and IDE teams 2 A common interventional model — procedural intervention vs daily eye drops 3 Large and active installed base. 400K+ IG and 75K+ IDE procedures performed to date 4 Two large, underserved markets in Glaucoma and Dry Eye 5 | 6 Scaling Interventional customer base 6
Page 7
A strategic roadmap to transform eyecare for glaucoma and dry eye patients by reducing patient burden, slowing disease progression, and improving outcomes. Embrace procedural intervention as a better alternative to medication management Intervene procedurally and address underlying disease over symptom management EMBRACE INTERVENE Identify patients who can benefit from procedural intervention as a better alternative to medication management IDENTIFY Activate the Path to Early Intervention EDUCATE Educate the patient on the benefits of procedural intervention | 7
Page 8
Interventional Dry Eye
Page 9
Dry Eye Disease | 9 - Linked to screen time, age (postmenopausal women, men 50+), systemic medication use - Predominantly managed with daily eye drops (compliance often poor) 1 Normal Mild Moderate Severe Large + Underserved Markets $2.4 billion US market for dry eye treatments 2 ~19 million U.S. patients diagnosed with dry eye disease 2 ¹ Uchino M. Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey. J Clin Med. 2022 Jan; 11(2): 367.1. ²2025 Market Scope Report.
Page 10
A new order of care Effective intervention shouldn’t wait, because meibomian gland dropout is irreversible and critical to ocular surface health1-3 TearCare targets the root cause of MGD: obstructed glands with demonstrated improvement of meibomian gland function4 SAHARA Results: TearCare was clinically superior in its primary signs endpoint (TBUT) as compared to Restasis, and showed significant improvements in all signs and symptoms 5 Published budget impact analysis demonstrates economic savings for payors as compared to a commonly used prescription dry eye medication 6 Providers can intervene sooner with the power to preserve CATEGORY 1 OTC/Compresses CATEGORY 2 Rx/Steroids CATEGORY 3 Non-Invasive (IPL, Plugs, Thermal) 1. Gutgesell VJ et al. Am J Ophthalmol. 1982;94(3):383-387. 2. Liu S, et al. Invest Ophthalmol Vis Sci. 2011;52(5):2727-2740. doi: 10.1167/iovs.10-6482. 3. Finis D, et al Curr Eye Res. 2015;40(10):982-989. doi:10.3109/02713683.2014.971929. 4. Gupta PK, et al. Cornea. 2022;41(4):417-426. doi:10.1097/ICO.0000000000002837. 5. Ayres BD, Bloomenstein M, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Perez V, Rodriguez T, Dickerson JE Jr. A randomized, controlled trial comparing TearCare and cyclosporine ophthalmic emulsion for the treatment of dry eye disease (SAHARA). Clin Ophthalmol 2023;17:3925-3940. 6. Chester T, Longo R, Masseria C, Riley P, Patel C, Mody L. Budget impact analysis (BIA) of the TearCare System for the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED) in the United States (US). Exp Rev Ophthalmol 2025;20: 55-61, DOI: 10.1080/17469899.2024.2444930
Page 11
MGD Opportunity U.S. patients diagnosed with Dry Eye Disease (DED) 1 Million DED patients Up to 86% of DED is associated with poor tear quality due to Meibomian Gland Dysfunction (MGD )1, 2 Million MGD patients ~50% of DED patients have moderate to severe symptoms 1 (most likely to seek treatment + targeted patient population in SAHARA RCT) Million moderate to severe MGD DED patients | 11 ¹ Market Scope 2025 Dry Eye Device Report. ² Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478.
Page 12
MGD is an Underserved Disease State The current market is dominated by eyedrops that do not address the underlying causes of MGD 1 | 12 Many dry eye treatments focus on increasing tear volume in aqueous deficient patients No interventional standard of care for treatment of MGD There is poor patient compliance with the use of Rx and OTC eyedrops for treatment 2 The US market for dry eye treatments was $2.4 billion in 2025 1 ¹ Market Scope 2025 Dry Eye Device Report and Dry Eye Pharmaceuticals Report and internal estimates. ² Uchino M. Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey. J Clin Med. 2022 Jan; 11(2): 367.1.
Page 13
| 13 TearCare Offers a Comprehensive Therapy Intervention Driving Leading Clinical Outcomes for Evaporative Dry Eye Disease Due to MGD OUR TECHNOLOGY: TEARCARE ¹ Estimate based on Dry Eye Treatment Lids shipped as of June 30, 2026. Comprehensive therapy to treat diseased meibomian glands Leading Clinical Trial Results: SAHARA, OLYMPIA >75K Procedures Performed 1
Page 14
TearCare: Designed to Preserve and Improve Gland Functionality | 14 TearCare is the only FDA-cleared interventional, open-eye, thermal-activated gland expression therapy designed to treat MGD conveniently and comfortably ¹ Gupta et al. Cornea 2022;41:417–426 Thin, wearable SmartLids® conform to the eyelid and allow natural blinking Precise, consistent, software- controlled thermal therapeutic melting cycle (at 45°C +/- 0.7°C for 15 minutes)¹ Comprehensive gland clearing protocol allows providers to manually evacuate the melted meibum comfortably 01 Application 02 Therapy 03 Expression Thermal Adaptive Gland Expression
Page 15
15 SAHARA: Randomized Controlled Trial comparing TearCare and Restasis®1 - Signs Superiority + Durability 2 - Head-to-Head Study TearCare vs Restasis1 - Large Trial (N=345) - Randomized - Assessor Masked - 3 Stages - Long-term (2-year trial) ¹ Restasis is a trademark of Allergan™ an AbbVie company ² Endpoints for SAHARA include superiority over Restasis at six months in our primary objective endpoint, tear break-up time. Study through 24 months to show duration of effectiveness. Ayres BD, Bloomenstein MR, Loh J, et al. A Randomized, Controlled Trial Comparing TearCare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA). Clin Ophthalmol. 2023;17:3925-3940. Hovanesian J, Ayres BD, Bloomenstein MR, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Rodriguez TC, Dickerson JE Jr. Durability of the TearCare treatment effect in subjects with dry eye disease: Stage 3 of the Sahara randomized controlled trial. Optom Vision Sci 2025;102:495-504 doi:10.1097/OPX.0000000000002278.
Page 16
SAHARA RCT: Results | 16 ¹ Endpoints for SAHARA include superiority over Restasis at six months in our primary objective endpoint, tear break-up time. TearCare treatment at Baseline and Month 5, Restasis twice a day for six months. Study through 24 months to show duration of effectiveness. ² Restasis is a trademark of Allergan™ an AbbVie company 3 Ocular Surface Disease Index is a commonly used patient-reported survey to assess dry eye severity. 4 Ayres BD, Bloomenstein M, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Rodriguez T, Dickerson JE Jr. Improved Signs and Symptoms of Dry Eye Disease for Restasis® Patients Following a Single Tearcare® Treatment: Phase 2 of the SAHARA Study. Clin Ophthalmol 2024;18:1525-1534 TearCare Superior to Restasis in Tear Breakup Time Improvement4 PHASE 1: TearCare Results at 6 Months • Superior to Restasis1, 2 in tear break-up time (TBUT) • Non-inferior to Restasis in ocular surface disease index (OSDI) 3 • Significant improvements in all signs and symptoms measured 0 0.5 1 1.5 2 2.5 Week 1 (P=.0001) Month 1 (P=.0055) Month 3 (P=.0080) Month 6 (P<.0001) Month 9 (Month 3 Crossover) (P<.001) Month 12 (Month 6 Crossover) (P<.001) Seconds Absolute Change from Baseline at Each Time Point TearCare Restasis • Patients previously treated with Restasis had additional clinically meaningful improvements in the signs and symptoms of DED when crossed over to TearCare at Month 6. These improvements persisted through Month twelve without continued Restasis use. • TBUT improved by an additional 1.1 seconds three months after cross-over to TearCare and improvement persisted (0.6 seconds) at month twelve, six months later PHASE 2: Restasis Cross-Over to TearCare Results at 12 Months Restasis Crossover to TearCare
Page 17
SAHARA RCT: Results | 17 ¹ 66% of TearCare® patients experienced dry eye relief for 2 years from study baseline. Study baseline refers to assessment at the start of SAHARA prior to any treatment and 5 months prior to the start of the Stage 3 durability stage. Months are measure d from Study Baseline. Error bars are ± 1 standard deviation. Hovanesian J, Ayres BD, Bloomenstein MR, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Rodriguez TC, Dickerson JE Jr. Durability of the TearCare treatment effect in subjects with dry eye disease: Stage 3 of the Sahara randomized controlled trial. Optom Vision Sci 2025;102:495-504 doi:10.1097/OPX.0000000000002278. 2 TearCare therapies in the first 5 months provided 2 years of relief for the majority of study patients1 PHASE 3: 24 Month Data • All mean signs and symptoms remained statistically significantly better than study baseline at all time points measured through the end of study at 24 months • Showed the durability and procedural treatment effect of TearCare - the majority (66%) of participants treated with TearCare at baseline and again at Month 5 required no additional treatment based on pre- defined retreatment criteria1 • Treatment twice per year can provide meaningful improvement and symptomatic relief for patients with moderate to severe dry eye. Seconds
Page 18
18 Interventional Dry Eye ¹ Estimated as of June 30, 2025 based on review of claims data and Company analytics 2 As of June 30, 2026 Scaling Commercially And Pursuing Expanded Market Access With the power of TearCare, we can: • Improve the lives of U.S. MGD patients • Scale commercial resources with market access wins • Target ~6,500 physicians identified as most likely to adopt MGD treatment procedures¹ • Activate a large installed customer base, over 75,000 SmartLids sold2, built across real-world testing and data collection since 2019 • Leverage synergies with our Interventional Glaucoma customer base and commercial infrastructure
Page 19
19 Interventional Glaucoma
Page 20
Glaucoma | 20 - Leading cause of irreversible blindness 1 - Predominantly managed with daily eye drops (compliance often poor) 2 Normal Mild Moderate Severe Large + Underserved Market ¹ Source: Market Scope 2025 report and JAMA Ophthalmology Prevalence of Glaucoma Among US Adults in 2022 Oct 17, 2024 . ² Newman-Casey PA, Robin AL, Blachley T, Farris KB, Heisler M, Resnicow K, Lee PP. The most common barriers to glaucoma medication adherence: A cross-sectional survey. Ophthalmology. 2015 Jul;122(7):1308-16. doi: 10.1016/j.ophtha.2015.03.026. ³ Represents Company analysis of third-party estimates in 2025. addressable U.S. market 3 U.S. patients diagnosed with Glaucoma 1$6 BILLION >4 MILLION
Page 21
POAG is similar to a clog in a kitchen sink: 01 TRABECULAR MESHWORK 02 SCHLEMM‘S CANAL 03 COLLECTOR CHANNELS 01 02 03 The conventional outflow pathway is an important focal point in treating POAG, the most common form of glaucoma The eye’s natural drainage system is called the conventional outflow pathway. Blockage of this system prevents aqueous fluid from draining. When aqueous fluid cannot drain, intraocular pressure (IOP) rises. Elevated IOP can lead to optic nerve damage and may result in irreversible blindness. Drain Cover (trabecular meshwork): allows excess aqueous fluid to enter drainage system 01 02 Sink Pipe (Schlemm’s Canal): conducts excess aqueous fluid to exit pathways known as collector channels 03 House Plumbing (collector channels): leads excess aqueous fluid out of the eye into the venous system Primary Open-Angle Glaucoma (POAG)
Page 22
| 22 OUR TECHNOLOGY: OMNI® SURGICAL SYSTEM OMNI Offers Leading Clinical Outcomes for Primary Open-Angle Glaucoma (POAG) ¹ Estimate based on units of OMNI (and predicates) and SION products shipped as of June 30, 2026 Comprehensive treatment of diseased conventional outflow pathway Leading clinical trial and registry results: ROMEO, GEMINI, AAO IRIS® Registry >400K Procedures Performed 1
Page 23
OMNI Comprehensively Treats the Conventional Outflow Pathway | 23 Minimally Invasive + Efficacious A comprehensive procedure enabled by the OMNI® Surgical System to help restore natural outflow in the eye with up to 360° treatment of all three areas of resistance* in the conventional outflow pathway * Trabecular meshwork, Schlemm’s Canal, and collector channels
Page 24
OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication AGIS-7 Findings3 <18 mmHg is the target IOP to limit the progression of glaucoma. On average, there was zero change in visual field defect score for patients whose IOP stayed below 18 mmHg over 6 years. OMNI is the most comprehensive implant-free Minimally Invasive Glaucoma Surgery (MIGS) technology, designed to effectively treat the full spectrum of primary open-angle glaucoma (POAG)1 OMNI with patented TruSync™ Technology is the only MIGS device with an FDA indication that allows for: o Use in combination cataract or standalone (without cataract) procedures o Access up to 360 degrees of the diseased conventional outflow pathway through a clear corneal microincision o Comprehensive treatment of all three areas of resistance2 in the diseased conventional outflow pathway o Use in adult patients with POAG across the spectrum of disease severity 1 Dickerson J, et al. Ab Interno Canaloplasty and Trabeculotomy Outcomes for Mild, Moderate, and Advanced Open-Angle Glaucoma: A ROMEO Analysis. Clin Ophthalmol. 2024: 18 1433-1440. 2 Trabecular meshwork, Schlemm’s Canal, and collector channels 3 The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators 4 GEMINI 36-month paper (Greenwood MR, Yadgarov A, Flowers BE, Sarkisian SR, Ohene-Nyako A, Dickerson JE Jr. 36-month outcomes from the prospective GEMINI study: canaloplasty and trabeculotomy combined with cataract surgery for patients with primary open-angle glaucoma. Clin Ophthalmol 2023;17:3817-3824.) 4
Page 25
25 Consistent Efficacy of OMNI in Combination Cataract (CC) and Standalone (SA) Clinical Trials COMBINATION CATARACT STANDALONE EFFICACY DEMONSTRATED OUT TO 3 YEARS 21.7 15.6 10 15 20 25 Unmedicated Baseline (n=17) Month 24 (n=17) GEMINI (12 Months)* ROMEO Elevated IOP CC (24 Months) ROMEO Elevated IOP SA (24 Months) TREY SA (11 Months)* GEMINI 2 IOP Outcomes CC (36 Months) GEMINI 2 # of Medications Outcomes CC (36 Months) IOP (mmHg)IOP (mmHg) IOP (mmHg)# of Medications 23.8 15.4 10 15 20 25 Unmedicated Baseline (n=113) Month 12 (n=113) 21.7 15.5 10 15 20 25 Unmedicated Baseline (n=22) Month 11 (n=22) 22.1 14.7 10 15 20 25 Unmedicated Baseline (n=17) Month 24 (n=17) 23.1 15.6 16.7 16.3 10 15 20 25 Baseline (n=66) Month 12 (n=66) Month 24 (n=66) Month 36 (n=62) 1.63 0.3 0.4 0.3 0 0.5 1 1.5 2 Baseline (n=66) Month 12 (n=66) Month 24 (n=66) Month 36 (n=62) References: GEMINI (Clin Ophthalmol. 2022;16:1225–1234); TREY (Int Ophthalmol (2022)); ROMEO 2 Year (Clin Ophthalmol. 2023:17 1057–1066); GEMINI 2: Greenwood MD et al. 36-Month Outcomes from the Prospective GEMINI Study: Canaloplasty and Trabeculotomy Combined with Cataract Surgery for Patients with Primary Open-Angle Glaucoma. Clinical Ophthalmology (December 2023). *Data refers to sub-populations of POAG patients
Page 26
OMNI Addresses All Six MIGS POAG Categories and Allows Surgeons to Customize Treatment | 26¹ Represents Company analysis of third-party estimates based on 2025 data MILD DISEASE (40%) MODERATE DISEASE (40%) ADVANCED DISEASE (20%) ~$2B opportunity ~$2B opportunity ~$1B opportunity ~$0.4B opportunity ~$0.4B opportunity ~$0.2B opportunity $5B Opportunity1 $1B Opportunity1 STANDALONE MIGS ~85%1 of POAG Eyes COMBINATION CATARACT MIGS ~15%1 of POAG Eyes MARKET OPPORTUNITY1
Page 27
Large and Unmet Clinical Need for Standalone MIGS Combination Cataract Standalone | 27 ~15% of POAG eyes1, ~90% of MIGS procedures1 Established, growing market Benefits from inherent IOP-lowering effect of cataract surgery Share-taking driven by efficacy, fast recovery times and attractive safety profile ~85% of POAG eyes¹, ~10% of MIGS procedures1 Large, underserved patient population MIGS procedure is the SOLE reason for operating room visit Standalone adoption requires a procedure with robust safety and efficacy, without the benefit of cataract surgery ¹ Represents Company analysis of third-party estimates based on 2025 data.
Page 28
MIGS for the Standalone Pseudophakic Patient The Glaucoma Patient Journey1 1 ESCRS. “Glaucoma Treatment Paradigm Shift.” By Dr. Karl Mercieca. EuroTimes. 2 Selective Laser Trabeculoplasty . Zone of unmet clinical need Pseudophakic POAG Patients 3-7 yrs post-op Glaucoma Diagnosis Patient diagnosed with glaucoma and begins their journey fighting the disease Topical Meds +/or SLT2 Prescribed glaucoma Rx and/or treated using a laser therapy Cataract +/- MIGS Now a candidate for cataract surgery, which may or may not include a MIGS procedure Topical Meds +/or SLT Disease progresses and prescribed glaucoma Rx and/or treated using a laser therapy Advanced Filtration Continues to progress until it needs to be treated with a trabeculectomy or tube shunt | 28
Page 29
29 Financial Performance SGHT DRY EYE GLAUCOMA Y/Y % Growth Q2 2026 Y/Y Revenue Growth FY26 Guidance Revenue $88M - $92M¹ Adj. OpEx² 92M - $94M¹ Historical financial results, including with respect to revenue and gross margin, may not be indicative of future financial results due to numerous risks and uncertainties, including those addressed in the "Risk Factors" section of the Company's filings with the U.S. Securities and Exchange Commission. ¹The Company expects full year 2026 revenue of approximately $88.0 to $92.0 million and adjusted operating expenses of $92.0 to $94.0 million, as of the Company's earnings release dated August 5, 2026. ²“Adjusted operating expenses” is a non-GAAP financial measure, which is calculated as operating expenses less stock-based compensation expense, depreciation and amortization, restructuring costs, and other one-time costs. For a reconciliation of adjusted operating expenses to operating expenses, please refer to our earnings release issued on August 5, 2026. $46.5 $65.6 $74.3 $75.9 $75.7 $79 – $81 $2.5 $5.7 $6.7 $4.0 $1.6 $9 - $11 FY21A FY22A FY23A FY24A FY25A FY26E $49 $71.3 $81.1 $79.9 $77.4 $88 - $92 Revenue CAGR FY21 to FY26* *based on midpoint of 2026 guidance +46% +14% -1% -3% +14 - 19%
Page 30
| 30 Keep Seeing TM